Change in personnel

NattoPharma ASA is announcing that VP for R&D and Regulatory Affairs Anne Bjørnebye Vik has terminated her full time engagement in the company as from September 28th 2009, and has signed a consultancy agreement with the company going forward. Dr. Vik has been instrumental in building up NattoPharma's scientific and regulatory basis for MenaQ7 since early 2006. She has also been responsible for NattoPharma's patent portfolio and QA. As previously announced, her responsibilities are now split between Dr. Leon Schurgers and Dr. Elke Theuwissen in VitaK in Maastricht. NattoPharma wants to thank Dr. Vik for her valuable contribution to development and positioning of the company.

For more information, please contact
Morten Sundstø,
NattoPharma ASA
Phone no. 0047 950 61 860

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.